CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to RHHBY

Trastuzumab deruxtecan

Phase 2
Roche Holding AG (RHHBY)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Apr '27
RHHBYPhase 2

Trastuzumab deruxtecan Phase 2 Est. Readout

Trastuzumab deruxtecan
Apr 2027~
CT.gov
00%
Competitive Landscape

1 competitor in HER2-positive Breast Cancer

View Full Landscape
Drug Information

Target Indication

HER2-positive Breast Cancer

Clinical Trial

NCT06172127

Last updated: 8/27/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.